2007
Identifying injection drug users at risk of nonfatal overdose.
Coffin P, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Academic Emergency Medicine 2007, 14: 616-23. PMID: 17554010, DOI: 10.1197/j.aem.2007.04.005.Peer-Reviewed Original ResearchConceptsDrug usersHabitual drug usersNonfatal overdoseAggressive prevention effortsAgonist maintenance treatmentSerious withdrawal symptomsInjection drug usersFurther longitudinal studiesIndividual-level risk factorsTake-home naloxoneOverdose prevention interventionsFuture overdosesMaintenance treatmentWithdrawal symptomsRisk factorsDrug overdoseRecent overdoseEmergency physiciansOverdose riskPrevention interventionsHigh riskOverdoseMedical careYounger ageU.S. adultsEarly immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users
Mehta S, Lucas G, Astemborski J, Kirk G, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007, 19: 637-645. PMID: 17505924, DOI: 10.1080/09540120701235644.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveDisease ProgressionFemaleHIV InfectionsHumansMaleMiddle AgedSubstance Abuse, IntravenousSurvival AnalysisTreatment OutcomeConceptsInjection drug usersActive antiretroviral therapyRisk of progressionVirologic responseTreatment interruptionImmunologic responseAntiretroviral therapyCommunity-based injection drug usersDrug usersMultiple Cox regression analysisRecent outpatient visitYears of HAARTCox regression analysisInjection drug useNew AIDS diagnosesSubsequent disease progressionEarly responseHAART initiationHAART initiatorsHIV careOutpatient visitsCox regressionPrognostic valueAIDS diagnosisPoor response
2006
Physical activity in a cohort of HIV-positive and HIV-negative injection drug users
Smit E, Crespo C, Semba R, Jaworowicz D, Vlahov D, Ricketts E, Ramirez-Marrero F, Tang A. Physical activity in a cohort of HIV-positive and HIV-negative injection drug users. AIDS Care 2006, 18: 1040-1045. PMID: 17012097, DOI: 10.1080/09540120600580926.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-positive participantsHIV-positive injection drug usersInjection drug useHIV-negativeVigorous activityPhysical activityDrug usersDrug usePaffenbarger Physical Activity QuestionnaireRecent injection drug usersHIV-negative injection drug usersIntravenous Experience cohortActive antiretroviral therapyCohort of HIVHIV-negative participantsPhysical Activity QuestionnairePhysical activity levelsAntiretroviral therapyHIV infectionViral loadHIV treatmentActivity QuestionnaireAnthropometric measurementsEnergy expenditure
2005
Injection Drug Use Is an Independent Risk Factor for Iron Deficiency and Iron Deficiency Anemia Among HIV-Seropositive and HIV-Seronegative Women
Dancheck B, Tang A, Thomas A, Smit E, Vlahov D, Semba R. Injection Drug Use Is an Independent Risk Factor for Iron Deficiency and Iron Deficiency Anemia Among HIV-Seropositive and HIV-Seronegative Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 198-201. PMID: 16186738, DOI: 10.1097/01.qai.0000165909.12333.07.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Iron-DeficiencyCase-Control StudiesFemaleHIV SeronegativityHIV SeropositivityHumansMiddle AgedSubstance Abuse, IntravenousConceptsInjection drug useIron deficiency anemiaHepatitis C virus statusFemale injection drug usersC virus statusInjection drug usersDeficiency anemiaDrug useIron deficiencyRisk factorsVirus statusDrug usersMultivariate analysisInjection drug use historyCD4 lymphocyte countHIV-seronegative womenIndependent risk factorHIV-positive womenCross-sectional studyFurther longitudinal studiesNatural history studiesIntravenous Experience (ALIVE) studyDrug use historyHIV-seropositiveLymphocyte countLiver enzyme values in injection drug users with chronic hepatitis C
Mehta S, Netski D, Sulkowski M, Strathdee S, Vlahov D, Thomas D. Liver enzyme values in injection drug users with chronic hepatitis C. Digestive And Liver Disease 2005, 37: 674-680. PMID: 15951255, DOI: 10.1016/j.dld.2005.03.009.Peer-Reviewed Original ResearchConceptsHepatitis C virusHepatitis C virus-infected personsAcute viral hepatitisLiver enzyme valuesVirus-infected personsC virusAminotransferase levelsViral hepatitisAlanine aminotransferaseAlanine aminotransferase/aspartate aminotransferase ratioChronic hepatitis C virus (HCV) infectionEnzyme valuesHepatitis C virus infectionAspartate aminotransferase ratioC virus infectionChronic hepatitis CHigher alanine aminotransferaseInjection drug usersHepatitis CAminotransferase ratioSerologic testingLiver enzymesULNVirus infectionDrug usersSexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy
Rusch M, Farzadegan H, Tarwater P, Safaeian M, Vlahov D, Strathdee S. Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy. AIDS And Behavior 2005, 9: 289-299. PMID: 16133905, DOI: 10.1007/s10461-005-9003-4.Peer-Reviewed Original ResearchConceptsInjection drug usersCondom useAntiretroviral therapyHIV testingDrug usersEligible injection drug usersRisk behaviorsActive antiretroviral therapyInconsistent condom useSexual risk behaviorsIDU cohortHIV transmissionRetrospective analysisLower riskStudy exposureSexual riskLong-term studiesTherapySignificant changesCounselingRiskExposureLogistic modelWidespread availabilityCohort
2004
Acceptance and completion of hepatitis B vaccination among drug users in New York City.
Ompad D, Galea S, Wu Y, Fuller C, Latka M, Koblin B, Vlahov D. Acceptance and completion of hepatitis B vaccination among drug users in New York City. Communicable Disease And Public Health 2004, 7: 294-300. PMID: 15779793.Peer-Reviewed Original ResearchConceptsDrug usersVaccine acceptanceHepatitis B vaccination ratesNon-injecting drug usersDaily crack usersPrevious HBV infectionHepatitis B vaccinationB vaccination ratesOngoing prospective studyB vaccinationDaily injectorsHBV testingHBV vaccinationVaccination seriesVaccine acceptorsHBV infectionVaccine seriesPrevious vaccinationRisk behavior questionnaireProspective studyVaccination acceptanceVaccination ratesSerological evidenceSeries completionVaccinationComparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities
Garfein R, Monterroso E, Tong T, Vlahov D, Des Jarlais D, Selwyn P, Kerndt P, Word C, Fernando M, Ouellet L, Holmberg S. Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities. Journal Of Urban Health 2004, 81: 260-267. PMID: 15136659, PMCID: PMC3456450, DOI: 10.1093/jurban/jth112.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFemaleHIV InfectionsHumansIncidenceLogistic ModelsMaleRisk FactorsRisk-TakingSubstance Abuse, IntravenousUnited StatesUrban HealthUrban PopulationConceptsInjection drug usersRisk behaviorsHIV seroprevalenceHigh human immunodeficiency virus (HIV) seroprevalenceDrug usersHIV infection risk behaviorsHuman immunodeficiency virus (HIV) seroprevalenceInfection risk behaviorsPotential risk factorsHIV risk behaviorsHIV incidenceHIV statusRisk factorsVirus seroprevalenceSexual partnersPrevention effortsSeroprevalenceBaseline dataHIVFace interviewsInjectionNew York CityFurther effortsNew HavenParticipantsIncrease in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users
Tun W, Gange S, Vlahov D, Strathdee S, Celentano D. Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users. Clinical Infectious Diseases 2004, 38: 1167-1174. PMID: 15095224, DOI: 10.1086/383033.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesFemaleHIV InfectionsHIV-1HumansMaleNeedle SharingRisk-TakingSafe SexSubstance Abuse, IntravenousConceptsInjection drug usersActive antiretroviral therapyHAART initiationCell countAntiretroviral therapyDrug usersSexual intercourseRisk reduction counselingHuman immunodeficiency virusLarge cohort studyDrug injection behaviorInjection of drugsUnprotected sexual intercourseSemiannual visitsReduction counselingCohort studyHIV infectionHIV serostatusImmunodeficiency virusImmunologic responseNeedle sharingBlood samplesSurvival analysisRisk behaviorsCD4Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City
Fuller C, Ompad D, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City. Journal Of Urban Health 2004, 81: 20-24. PMID: 15047780, PMCID: PMC3456148, DOI: 10.1093/jurban/jth084.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCohort StudiesHepacivirusHepatitis CHumansIncidenceNeedle SharingNew York CityRisk FactorsRisk-TakingSubstance Abuse, IntravenousConceptsHepatitis C virusInjection drug usersNoninjection drug usersDrug usersHCV seropositiveRisk of HCVNew injection drug usersPerson-time analysisAnnual incidence rateHepatitis C incidenceAnnual incident rateHigh-risk practicesHCV incidenceHCV seroconvertersNon-IDUsHCV serologyHCV preventionC virusRisk factorsIncidence ratePrevention servicesOnset of injectionEarly preventionNew York CityRisk SurveyExplaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City.
Fuller C, Galea S, Blaney S, Ompad D, Deren S, Des Jarlais D, Vlahov D. Explaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City. Ethnicity & Disease 2004, 14: 589-96. PMID: 15724781.Peer-Reviewed Original Research
2003
Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection
Royal W, Vlahov D, Lyles C, Gajewski C. Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases 2003, 37: s427-s432. PMID: 14648459, DOI: 10.1086/377554.Peer-Reviewed Original ResearchMeSH KeywordsAIDS Dementia ComplexCytokinesHIV InfectionsHIV-1HumansMorphineNervous System DiseasesPrealbuminRetinoidsRetinol-Binding ProteinsSubstance Abuse, IntravenousSubstance-Related DisordersConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionType 1 infectionDrug usersSeronegative control subjectsRetinoic acidDevelopment of HIVInjection drug usersTumor necrosis factorNervous system diseasesLevels of retinolMononuclear cell lineNeurological disease riskTrans retinoic acidDrugs of abuseRetinoid administrationClinical outcomesRetinol-binding proteinImmunomodulatory effectsControl subjectsNecrosis factorSystem diseasesNeurological diseasesHIVDisease riskLongitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano D. Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants. American Journal Of Epidemiology 2003, 158: 695-704. PMID: 14507606, DOI: 10.1093/aje/kwg209.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug injection behaviorDrug usersIntravenous Experience (ALIVE) studyDrug treatment programsHistory of incarcerationLogistic regression modelsALIVE studySemiannual visitsMultinomial logistic regression modelsBaseline factorsChronic diseasesDrug injectionRecent overdoseCessation attemptsDrug use transitionsDrug injectorsCommunity outreach effortsLongitudinal patternsHigh mortalityEarly determinantsYounger ageTreatment programInjection behaviorStudy periodThe Role of Medicaid HMO Enrollment in the Longitudinal Utilization of Medical Care Services in a Cohort of Injecting Drug users in Baltimore, Maryland
Juday T, Wu A, Celentano D, Rick K, Wang M, Vlahov D. The Role of Medicaid HMO Enrollment in the Longitudinal Utilization of Medical Care Services in a Cohort of Injecting Drug users in Baltimore, Maryland. Substance Use & Addiction Journal 2003, 24: 27-41. PMID: 12652093, DOI: 10.1080/08897070309511531.Peer-Reviewed Original ResearchConceptsAmbulatory care visitsCare visitsInpatient admissionsHMO enrollmentDrug usersMedicaid HMO enrolleesMore inpatient admissionsInjecting Drug UsersMedical care utilizationNatural history studiesIntravenous Experience (ALIVE) studyMedical care servicesCommunity-based sampleLongitudinal utilizationER visitsHIV infectionCare utilizationMedicaid beneficiariesHMO enrolleesCare servicesIDUsInappropriate utilizationUtilization differencesMedicaidMedicaid HMOsFactors Associated With Human Herpesvirus Type 8 Infection in an Injecting Drug User Cohort
Bernstein K, Jacobson L, Jenkins F, Vlahov D, Armenian H. Factors Associated With Human Herpesvirus Type 8 Infection in an Injecting Drug User Cohort. Sexually Transmitted Diseases 2003, 30: 199-204. PMID: 12616135, DOI: 10.1097/00007435-200303000-00004.Peer-Reviewed Original ResearchConceptsHHV-8 seroprevalenceRisk factorsHHV-8Human herpesvirus type 8 infectionLarger body mass indexHuman herpesvirus type 8Drug user cohortHHV-8 seropositivityInjection drug useBody mass indexMultivariate logistic regressionCross-sectional studyDrug user populationGenital wartsMass indexGeneral populationDrug useSeroprevalenceIndirect immunofluorescenceLogistic regressionIDUsInfectionType 8User cohortSexual behaviorVariability in the Incidence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection among Young Injecting Drug Users in New York City
Des Jarlais D, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman S, Monterroso E, Williams I, Garfein R. Variability in the Incidence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection among Young Injecting Drug Users in New York City. American Journal Of Epidemiology 2003, 157: 467-471. PMID: 12615611, DOI: 10.1093/aje/kwf222.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCohort StudiesFemaleHepatitis BHepatitis CHIV InfectionsHumansIncidenceInterviews as TopicMaleNew York CityRisk-TakingSexual BehaviorSubstance Abuse, IntravenousConceptsHepatitis B virusHuman immunodeficiency virusHepatitis C virusImmunodeficiency virusB virusDrug usersHepatitis C virus infectionC virus infectionInjecting Drug UsersHigh HIV seroprevalenceHigh rateHBV incidenceHCV incidenceHCV transmissionCohort studyHIV seroprevalenceHIV incidenceHIV transmissionYoung Injecting Drug UsersC virusVirus infectionNew York CityIncidenceVirusYork CitySocial Circumstances of Initiation of Injection Drug Use and Early Shooting Gallery Attendance: Implications for HIV Intervention Among Adolescent and Young Adult Injection Drug Users
Fuller C, Vlahov D, Latkin C, Ompad D, Celentano D, Strathdee S. Social Circumstances of Initiation of Injection Drug Use and Early Shooting Gallery Attendance: Implications for HIV Intervention Among Adolescent and Young Adult Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2003, 32: 86. PMID: 12514419, DOI: 10.1097/00126334-200301010-00013.Peer-Reviewed Original ResearchConceptsInjection drug usersNew injection drug usersOlder injection drug usersYoung adult injection drug usersDrug usersHigh-risk injection drug usersStreet-recruited injection drug usersAdult injection drug usersYoung injection drug usersGallery attendanceProspective cohort studyInjection drug useMultiple logistic regressionHigh-risk practicesCohort studyMedian ageHIV incidenceHIV prevalenceInnovative intervention strategiesHIV interventionsDrug useLogistic regressionHIVBaseline dataMost participants
2002
Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users?
Kapadia F, Vlahov D, Jarlais D, Strathdee S, Ouellet L, Kerndt P, E E, Williams I, Garfein R. Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users? Epidemiology 2002, 13: 738-741. PMID: 12410020, DOI: 10.1097/00001648-200211000-00023.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesDisinfectionFemaleHepatitis CHepatitis C AntibodiesHumansMaleNeedle SharingOdds RatioSubstance Abuse, IntravenousSyringesUnited StatesConceptsInjection drug usersAnti-HCV seroconversionHepatitis C virusDrug usersOdds ratioBleach useYoung adult injection drug usersSeronegative injection drug usersMajor public health problemAdult injection drug usersBleach disinfectionHepatitis C infectionProspective cohort studyCase-control studyConditional logistic regressionPublic health problemCessation of injectionsC infectionHCV infectionCohort studyC virusProtective effectHealth problemsSeroconversionLogistic regressionImpact of Increased Syringe Access: Preliminary Findings on Injection Drug User Syringe Source, Disposal, and Pharmacy Sales in Harlem, New York
Fuller C, Ahern J, Vadnai L, Coffin P, Galea S, Factor S, Vlahov D. Impact of Increased Syringe Access: Preliminary Findings on Injection Drug User Syringe Source, Disposal, and Pharmacy Sales in Harlem, New York. Journal Of The American Pharmacists Association 2002, 42: s77-s82. PMID: 12489621, DOI: 10.1331/1086-5802.42.0.s77.fuller.Peer-Reviewed Original ResearchHighly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users
Bouhnik A, Moatti J, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. Journal Of Epidemiology & Community Health 2002, 56: 349. PMID: 11964431, PMCID: PMC1732133, DOI: 10.1136/jech.56.5.349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveFemaleFollow-Up StudiesFranceHIV InfectionsHumansMaleProspective StudiesRisk-TakingSexual BehaviorSubstance Abuse, IntravenousConceptsSexual risk behaviorsAntiretroviral treatmentDrug usersRisk behaviorsPrescription of HAARTActive antiretroviral therapyProportion of patientsActive antiretroviral treatmentUnprotected sexual intercourseFrench HIVAntiretroviral therapyClinical improvementCohort studyTreatment-NaiveHIV transmissionAIDS careHAARTHIV riskHigh-risk activitiesHospital departmentsSexual riskHIVSexual intercourseMultivariate modelLongitudinal analysis